Vaccins à ARN messager contre le Covid-19 : piqûre de rappel [mRNA Covid vaccines: What do we know eight months after deployment]

Détails

Ressource 1Télécharger: RMS_758_1910.pdf (116.45 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY-NC-ND 4.0
ID Serval
serval:BIB_CE2F5557994E
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Vaccins à ARN messager contre le Covid-19 : piqûre de rappel [mRNA Covid vaccines: What do we know eight months after deployment]
Périodique
Revue medicale suisse
Auteur⸱e⸱s
Miauton A., Besson J., Muller Y., Genton B.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
10/11/2021
Peer-reviewed
Oui
Volume
17
Numéro
758
Pages
1910-1914
Langue
français
Notes
Publication types: Journal Article
Publication Status: publish
Résumé
This paper summarizes the main knowledge on mRNA vaccines in September 2021. The only contraindication for a 1st dose of vaccine is an allergy to one of the components of the vaccine, but a specialized consultation is possible for an eventual split vaccination under medical supervision. Serious side effects are rare and consist mainly of myocarditis, shingles and appendicitis, but the risk/benefit ratio is always favorable for vaccination. Efficacy against severe COVID-19 is > 90 % after 6 months, and this against all variants. It is recommended to vaccinate pregnant women. A 3rd dose is not recommended at this time, except for immunosuppressed individuals without detectable antibodies after 2 doses. Vaccine mixing is possible, including with a viral vector vaccine.
Mots-clé
COVID-19/prevention & control, COVID-19 Vaccines, Female, Humans, Pregnancy, RNA, Messenger, Vaccination, Vaccines, Synthetic
Pubmed
Création de la notice
15/11/2021 17:13
Dernière modification de la notice
21/11/2022 8:28
Données d'usage